LONA

LeonaBio, Inc.

Name: LeonaBio, Inc. insider trading (SEC Form 4) history
Creator: U.S. Securities and Exchange Commission

SEC CIK 1620463

$8.49 +82.6% · 90 days

90-day buys

0 open-market

90-day sells

0 open-market

Net insider flow

+$0

Net buying

Filings shown

Most recent

At a glance

Insiders at LONA have made no open-market trades in the last 90 days — the activity below is grants, option exercises, and other routine filings.

Largest recent trade: Litton Mark James sold $27.7K of LONA, trimming their stake 8%.

Most active filer: Renninger Robert, with 8 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for LONA, newest first

View on SEC EDGAR ↗

LONA

LeonaBio, Inc.

Sell Litton Mark James · Director, PRESIDENT and CEO · Open-market sale · filed Mar 5, 2026 ΔOwn −8.2%

Litton Mark James sold $27.7K of LONA, trimming their stake 8%.

−$27.7K

5,156 sh @ $5

LONA

LeonaBio, Inc.

Sell Renninger Robert · CHIEF FINANCIAL OFFICER · Open-market sale · filed Mar 5, 2026 ΔOwn −5.4%

Renninger Robert sold $4.9K of LONA, trimming their stake 5%.

−$4.9K

906 sh @ $5

LONA

LeonaBio, Inc.

Sell Worthington Mark · GENERAL COUNSEL and CCO · Open-market sale · filed Mar 5, 2026 ΔOwn −6.7%

Worthington Mark sold $7.1K of LONA, trimming their stake 7%.

−$7.1K

1,328 sh @ $5

LONA

LeonaBio, Inc.

Sell CHURCH KEVIN · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Mar 5, 2026 ΔOwn −5.1%

Church Kevin sold $7.3K of LONA, trimming their stake 5%.

−$7.3K

1,359 sh @ $5

LONA

LeonaBio, Inc.

Sell San Martin Javier · CHIEF MEDICAL OFFICER · Open-market sale · filed Mar 5, 2026 ΔOwn −9.8%

San Martin Javier sold $9.2K of LONA, trimming their stake 10%.

−$9.2K

1,720 sh @ $5

LONA

LeonaBio, Inc.

Option exercise Litton Mark James · Director, PRESIDENT and CEO · Option exercise · filed Mar 5, 2026 ΔOwn +55%

+$0

22,254 sh

LONA

LeonaBio, Inc.

Option exercise Renninger Robert · CHIEF FINANCIAL OFFICER · Option exercise · filed Mar 5, 2026 ΔOwn +30%

+$0

3,900 sh

LONA

LeonaBio, Inc.

Option exercise Worthington Mark · GENERAL COUNSEL and CCO · Option exercise · filed Mar 5, 2026 ΔOwn +41%

+$0

5,726 sh

LONA

LeonaBio, Inc.

Option exercise CHURCH KEVIN · CHIEF SCIENTIFIC OFFICER · Option exercise · filed Mar 5, 2026 ΔOwn +28%

+$0

5,856 sh

LONA

LeonaBio, Inc.

Option exercise San Martin Javier · CHIEF MEDICAL OFFICER · Option exercise · filed Mar 5, 2026 ΔOwn +73%

+$0

7,418 sh

ATHA

Athira Pharma, Inc.

Sell San Martin Javier · CHIEF MEDICAL OFFICER · Open-market sale · filed Jan 5, 2026 ΔOwn −14%

San Martin Javier sold $11.3K of ATHA, trimming their stake 14%.

−$11.3K

1,644 sh @ $7

ATHA

Athira Pharma, Inc.

Sell Litton Mark James · Director, President and CEO · Open-market sale · filed Jan 5, 2026 ΔOwn −6.0%

Litton Mark James sold $17.8K of ATHA, trimming their stake 6%.

−$17.8K

2,586 sh @ $7

ATHA

Athira Pharma, Inc.

Sell Renninger Robert · Chief Financial Officer · Open-market sale · filed Jan 5, 2026 ΔOwn −2.3%

Renninger Robert sold $2K of ATHA, trimming their stake 2%.

−$2K

297 sh @ $7

ATHA

Athira Pharma, Inc.

Sell CHURCH KEVIN · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Jan 5, 2026 ΔOwn −4.1%

Church Kevin sold $6K of ATHA, trimming their stake 4%.

−$6K

876 sh @ $7

ATHA

Athira Pharma, Inc.

Sell Worthington Mark · General Counsel and CCO · Open-market sale · filed Jan 5, 2026 ΔOwn −5.9%

Worthington Mark sold $6K of ATHA, trimming their stake 6%.

−$6K

876 sh @ $7

ATHA

Athira Pharma, Inc.

Option exercise San Martin Javier · CHIEF MEDICAL OFFICER · Option exercise · filed Jan 5, 2026 ΔOwn +65%

+$0

4,667 sh

ATHA

Athira Pharma, Inc.

Option exercise Litton Mark James · Director, President and CEO · Option exercise · filed Jan 5, 2026 ΔOwn +33%

+$0

10,834 sh

ATHA

Athira Pharma, Inc.

Option exercise Renninger Robert · Chief Financial Officer · Option exercise · filed Jan 5, 2026 ΔOwn +10%

+$0

1,236 sh

ATHA

Athira Pharma, Inc.

Option exercise CHURCH KEVIN · CHIEF SCIENTIFIC OFFICER · Option exercise · filed Jan 5, 2026 ΔOwn +20%

+$0

3,667 sh

ATHA

Athira Pharma, Inc.

Option exercise Worthington Mark · General Counsel and CCO · Option exercise · filed Jan 5, 2026 ΔOwn +33%

+$0

3,667 sh

ATHA

Athira Pharma, Inc.

Grant/award PERCEPTIVE ADVISORS LLC · Director, 10% Owner · Grant/award · filed Dec 23, 2025 ΔOwn +183%

+$6.28M

989,270 sh @ $6

ATHA

Athira Pharma, Inc.

Grant/award PERCEPTIVE ADVISORS LLC · Director, 10% Owner · Grant/award · filed Dec 23, 2025 ΔOwn NEW

+$2.09M

329,756 sh @ $6

ATHA

Athira Pharma, Inc.

Grant/award Renninger Robert · Chief Financial Officer · Grant/award · filed Jan 5, 2026 ΔOwn +9.2%

+$2.3K

1,000 sh @ $2

ATHA

Athira Pharma, Inc.

Grant/award CHURCH KEVIN · CHIEF SCIENTIFIC OFFICER · Grant/award · filed Jan 5, 2026 ΔOwn +5.9%

+$2.3K

1,000 sh @ $2

ATHA

Athira Pharma, Inc.

Sell CHURCH KEVIN · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Jul 2, 2025 ΔOwn −4.8%

Church Kevin sold $2.5K of ATHA, trimming their stake 5%.

−$2.5K

8,526 sh @ $0

ATHA

Athira Pharma, Inc.

Sell Litton Mark James · Director, President and CEO · Open-market sale · filed Jul 2, 2025 ΔOwn −7.2%

Litton Mark James sold $7.4K of ATHA, trimming their stake 7%.

−$7.4K

25,123 sh @ $0

ATHA

Athira Pharma, Inc.

Sell San Martin Javier · CHIEF MEDICAL OFFICER · Open-market sale · filed Jul 2, 2025 ΔOwn −13%

San Martin Javier sold $3.2K of ATHA, trimming their stake 13%.

−$3.2K

10,842 sh @ $0

ATHA

Athira Pharma, Inc.

Sell Worthington Mark · General Counsel and CCO · Open-market sale · filed Jul 2, 2025 ΔOwn −7.1%

Worthington Mark sold $2.5K of ATHA, trimming their stake 7%.

−$2.5K

8,526 sh @ $0

ATHA

Athira Pharma, Inc.

Sell Renninger Robert · SVP, Finance and Accounting · Open-market sale · filed Jul 2, 2025 ΔOwn −2.6%

Renninger Robert sold $850 of ATHA, trimming their stake 3%.

−$850

2,897 sh @ $0

ATHA

Athira Pharma, Inc.

Option exercise CHURCH KEVIN · CHIEF SCIENTIFIC OFFICER · Option exercise · filed Jul 2, 2025 ΔOwn +26%

+$0

36,666 sh

About LONA insider activity

This page tracks every recent Form 4 filed for LeonaBio, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is LONA insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for LeonaBio, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.